Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Optimized flow cytometry assay for functional characterization of variants of uncertain significance in familial hypercholesterolemia.

Atherosclerosis·2026

Same author

Managing remnant cholesterol: role of fenofibrate-statin therapy in reducing triglyceride-rich lipoproteins.

Frontiers in cardiovascular medicine·2026

Same author

Pathogenic interplay between markedly elevated plasma lipoprotein(a) levels and prothrombotic mechanisms: a case report.

Frontiers in cardiovascular medicine·2026

Same author

Focus on lipoprotein(a).

European heart journal supplements : journal of the European Society of Cardiology·2026

Same author

Lipid management in type 2 diabetes and non-HDL-cholesterol: target all atherogenic lipoproteins.

Cardiovascular diabetology·2026

Same author

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24-Month Follow-Up From the Italian Registry.

Annals of clinical and translational neurology·2026

Search research articles

Related Experiment Video

Updated: Jun 18, 2025

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Lessons from PROMINENT and prospects for pemafibrate.

Jean-Charles Fruchart¹, Jamila Fruchart-Najib², Shizuya Yamashita^3,4,5

¹Residual Risk Reduction Initiative (R3i) Foundation, Picassoplatz 8, Basel, 4010, Switzerland. jean-charles.fruchart@r3i.org.

Cardiovascular Diabetology

|July 31, 2024

Summary

This summary is machine-generated.

The PROMINENT trial showed pemafibrate did not reduce cardiovascular events. However, pemafibrate may benefit diabetic microangiopathy and non-alcoholic fatty liver disease, warranting further investigation.

Area of Science:

Cardiovascular medicine
Metabolic diseases
Pharmacology

Background:

The PROMINENT trial evaluated pemafibrate for cardiovascular risk reduction.

Keywords:

Diabetic retinopathy PROMINENT trial Pemafibrate Peripheral artery disease Type 2 diabetes mellitus

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Expression, Purification, Crystallization, and Enzyme Assays of Fumarylacetoacetate Hydrolase Domain-Containing Proteins

Expression, Purification, Crystallization, and Enzyme Assays of Fumarylacetoacetate Hydrolase Domain-Containing Proteins

Published on: June 20, 2019

Related Experiment Videos

Last Updated: Jun 18, 2025

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Expression, Purification, Crystallization, and Enzyme Assays of Fumarylacetoacetate Hydrolase Domain-Containing Proteins

Expression, Purification, Crystallization, and Enzyme Assays of Fumarylacetoacetate Hydrolase Domain-Containing Proteins

Published on: June 20, 2019

Pemafibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist.

The trial yielded neutral results regarding its primary efficacy endpoint.